Cytori Therapeutics (CYTX) Stock Price Up -9.3%
Cytori Therapeutics Inc (NASDAQ:CYTX) rose 9.3% on Tuesday . The company traded as high as $0.46 and last traded at $0.39. Approximately 13,941 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 375,664 shares. The stock had previously closed at $0.43.
CYTX has been the topic of a number of research reports. ValuEngine upgraded Cytori Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, July 2nd. HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Cytori Therapeutics in a report on Wednesday, July 11th. Zacks Investment Research upgraded Cytori Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 11th. Finally, Maxim Group cut Cytori Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 15th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Cytori Therapeutics has a consensus rating of “Buy” and an average target price of $10.56.
The firm has a market cap of $3.13 million, a P/E ratio of -0.06 and a beta of 2.52.
Cytori Therapeutics Company Profile (NASDAQ:CYTX)
Cytori Therapeutics, Inc, a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types.
See Also: What is dollar cost averaging (DCA)?
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.